1433 related articles for article (PubMed ID: 32428551)
41. A germline mutation (A339V) in thyroid transcription factor-1 (TITF-1/NKX2.1) in patients with multinodular goiter and papillary thyroid carcinoma.
Ngan ES; Lang BH; Liu T; Shum CK; So MT; Lau DK; Leon TY; Cherny SS; Tsai SY; Lo CY; Khoo US; Tam PK; Garcia-Barceló MM
J Natl Cancer Inst; 2009 Feb; 101(3):162-75. PubMed ID: 19176457
[TBL] [Abstract][Full Text] [Related]
42. Cytological features of warthin-like papillary thyroid carcinoma: A case report with review of previous cytology cases.
Vallonthaiel AG; Agarwal S; Jain D; Yadav R; Damle NA
Diagn Cytopathol; 2017 Sep; 45(9):837-841. PubMed ID: 28449420
[TBL] [Abstract][Full Text] [Related]
43. [Comments on the Ito et al. article (Endocr J. 2008 Oct 8. Epub ahead of print)] The lack of clinicopathological correlation of BRAF mutation in papillary thyroid cancer needs to be interpreted with caution.
Xing M
Endocr J; 2009; 56(2):305-6; author reply 307-8. PubMed ID: 19047780
[No Abstract] [Full Text] [Related]
44. Letter regarding the article: "Multiple HABP2 variants in familial papillary thyroid carcinoma: Contribution of a group of "thyroid-checked" controls" by Kern et al.
Colombo C; Fugazzola L; Muzza M; Proverbio MC; Cirello V
Eur J Med Genet; 2018 Feb; 61(2):104-105. PubMed ID: 28779995
[TBL] [Abstract][Full Text] [Related]
45. Coexistence of paraganglioma/pheochromocytoma and papillary thyroid carcinoma: a four-case series analysis.
Bugalho MJ; Silva AL; Domingues R
Fam Cancer; 2015 Dec; 14(4):603-7. PubMed ID: 26071763
[TBL] [Abstract][Full Text] [Related]
46. The spectrum of papillary thyroid carcinoma variants.
Khanafshar E; Lloyd RV
Adv Anat Pathol; 2011 Jan; 18(1):90-7. PubMed ID: 21169742
[TBL] [Abstract][Full Text] [Related]
47. Identification of Unique, Heterozygous Germline Mutation, STK11 (p.F354L), in a Child with an Encapsulated Follicular Variant of Papillary Thyroid Carcinoma within Six Months of Completing Treatment for Neuroblastoma.
Buryk MA; Picarsic JL; Creary SE; Shaw PH; Simons JP; Deutsch M; Monaco SE; Nikiforov YE; Witchel SF
Pediatr Dev Pathol; 2015; 18(4):318-23. PubMed ID: 25751324
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of mutation profiling by matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry in fine needle aspirations from papillary thyroid cancer.
Woo HI; Kim SW; Ki CS; Shin JH; Oh YL; Kim JW; Chung JH
Clin Chem Lab Med; 2014 Jul; 52(7):e139-42. PubMed ID: 24561361
[No Abstract] [Full Text] [Related]
49. Noninvasive Follicular Thyroid Neoplasms With Papillary-like Nuclear Features Are Genetically and Biologically Similar to Adenomatous Nodules and Distinct From Papillary Thyroid Carcinomas With Extensive Follicular Growth.
Johnson DN; Furtado LV; Long BC; Zhen CJ; Wurst M; Mujacic I; Kadri S; Segal JP; Antic T; Cipriani NA
Arch Pathol Lab Med; 2018 Jul; 142(7):838-850. PubMed ID: 29582677
[TBL] [Abstract][Full Text] [Related]
50. miR-146a and miR-146b in the diagnosis and prognosis of papillary thyroid carcinoma.
Qiu Z; Li H; Wang J; Sun C
Oncol Rep; 2017 Nov; 38(5):2735-2740. PubMed ID: 29048684
[TBL] [Abstract][Full Text] [Related]
51. Letter to the Editor regarding the paper by N. Azzam et al. 'Germline polymorphisms on RET proto-oncogene involved in medullary thyroid carcinoma in a Druze family'.
Mathiesen JS; Godballe C; Brusgaard K
Eur J Cancer; 2018 Apr; 93():154-155. PubMed ID: 29433789
[No Abstract] [Full Text] [Related]
52. Multigenerational familial medullary thyroid cancer (FMTC): evidence for FMTC phenocopies and association with papillary thyroid cancer.
Fugazzola L; Cerutti N; Mannavola D; Ghilardi G; Alberti L; Romoli R; Beck-Peccoz P
Clin Endocrinol (Oxf); 2002 Jan; 56(1):53-63. PubMed ID: 11849247
[TBL] [Abstract][Full Text] [Related]
53. Primary hyperparathyroidism, C-cell hyperplasia and papillary thyroid carcinoma in a patient with RET germline polymorphism S836S.
Brauckhoff M; Gimm O; Bilkenroth U; Hinze R; Dralle H
Langenbecks Arch Surg; 2002 Oct; 387(5-6):201-3. PubMed ID: 12410354
[TBL] [Abstract][Full Text] [Related]
54. BRAF genetic heterogeneity in papillary thyroid carcinoma and its metastasis.
Walts AE; Pao A; Sacks W; Bose S
Hum Pathol; 2014 May; 45(5):935-41. PubMed ID: 24746198
[TBL] [Abstract][Full Text] [Related]
55. Characterization and significance of MUC1 and c-myc expression in elderly patients with papillary thyroid carcinoma.
Hu YJ; Luo XY; Yang Y; Chen CY; Zhang ZY; Guo X
Genet Mol Res; 2015 Nov; 14(4):15325-30. PubMed ID: 26634497
[TBL] [Abstract][Full Text] [Related]
56. Germline Variants in DNA Repair Genes, Diagnostic Radiation, and Risk of Thyroid Cancer.
Sandler JE; Huang H; Zhao N; Wu W; Liu F; Ma S; Udelsman R; Zhang Y
Cancer Epidemiol Biomarkers Prev; 2018 Mar; 27(3):285-294. PubMed ID: 29263185
[No Abstract] [Full Text] [Related]
57. Molecular Profiling of Papillary Thyroid Carcinoma in Korea with a High Prevalence of BRAF
Lee SE; Hwang TS; Choi YL; Kim WY; Han HS; Lim SD; Kim WS; Yoo YB; Kim SK
Thyroid; 2017 Jun; 27(6):802-810. PubMed ID: 28293988
[TBL] [Abstract][Full Text] [Related]
58. Targeted next generation sequencing identifies somatic mutations and gene fusions in papillary thyroid carcinoma.
Lu Z; Zhang Y; Feng D; Sheng J; Yang W; Liu B
Oncotarget; 2017 Jul; 8(28):45784-45792. PubMed ID: 28507274
[TBL] [Abstract][Full Text] [Related]
59. Does mutational analysis influence the management of differentiated thyroid cancers?
Asarkar A; Shaha M; Shaha A; Nathan CO
Laryngoscope; 2018 Jan; 128(1):1-2. PubMed ID: 28514497
[No Abstract] [Full Text] [Related]
60. Genomic Characterization of Differentiated Thyroid Carcinoma.
Song YS; Park YJ
Endocrinol Metab (Seoul); 2019 Mar; 34(1):1-10. PubMed ID: 30912334
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
